Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The rivalry between the two biggest names in weight loss medicine just moved into a federal courtroom.
Novo Nordisk filed a lawsuit against Eli Lilly on July 21, 2026. The company filed it in the U.S. District Court for the District of New Jersey. Novo claims Lilly ran misleading ads for its blockbuster drugs Zepbound and Mounjaro. Specifically, Novo alleges Lilly violated the federal Lanham Act, the law that governs false advertising claims between competing businesses.
So what exactly is Novo upset about? Ultimately, it comes down to dosing.
Novo says Lilly’s Zepbound ads compare that drug’s highest dose against much lower doses of Wegovy. That comparison leaves out a key detail, according to the complaint. Back in March 2026, the FDA approved a stronger 7.2 milligram dose of Wegovy. Lilly’s campaigns simply don’t mention it.
A similar issue shows up with Mounjaro. Novo alleges that Lilly’s ads pit Mounjaro’s top 15 milligram dose against just 1 milligram of Ozempic. That comparison is notable because Ozempic’s FDA-approved 2 milligram maintenance dose has been available for years. Comparing a top-tier dose against a starter dose, Novo argues, creates a skewed picture for consumers.
This isn’t the first time Novo raised the issue, either. Back in April 2026, the company reportedly sent Lilly a cease and desist letter. Instead of pulling the ads, Lilly added a disclaimer. However, Novo says the fine print doesn’t fix the overall impression the ads create.
Now Novo wants more. The lawsuit asks the court to force Lilly to withdraw the disputed ads. It also wants Lilly to run a corrective campaign in their place.
Lilly, for its part, isn’t backing down. The company points to its 2024 SURMOUNT-5 trial as the basis for its marketing. That study compared 10 and 15 milligram doses of Zepbound against 1.7 and 2.4 milligram doses of Wegovy. A Lilly spokesperson called it the only head-to-head, randomized trial comparing tirzepatide and semaglutide for weight management. Notably, Lilly says it stands by its advertising and plans to fight the lawsuit.
For anyone taking these drugs, or thinking about starting one, a quick refresher helps. Wegovy and Ozempic both use semaglutide. Zepbound and Mounjaro both use tirzepatide. Both drug classes fall under the GLP-1 receptor agonist umbrella. Essentially, they work by influencing appetite and blood sugar regulation. All four require a prescription, and they’re approved for chronic weight management, type 2 diabetes, or sometimes both.
Legally speaking, this case stands out. Pharmaceutical companies sue each other over patents fairly often. In contrast, false advertising suits under the Lanham Act happen much less frequently. For that reason, the case is worth watching closely. Its outcome could shape how drugmakers support comparative effectiveness claims in future ad campaigns.
There’s also a bigger business story unfolding here. Novo has leaned hard into its oral version of Wegovy. That product has held up well against Lilly’s own oral tirzepatide pill. Meanwhile, Novo replaced its CEO last year after issuing multiple profit warnings. Obesity treatment has become one of the most lucrative and closely watched corners of American medicine, carrying real weight for the cost of care nationwide. Altogether, this lawsuit lands right in the middle of a broader fight for market share in that fast-growing space, and it likely won’t be the last chapter in this rivalry.
